OBN is the Membership organisation supporting and bringing together the UK’s emerging life sciences companies, corporate partners and investors. Our 380-plus Member companies are located across the Golden Triangle and beyond to Nottingham, Manchester and Scotland benefiting from our networking, partnering, purchasing, advising and advocacy activities.
OBN BioTuesday Debate: How Will Megafunds Impact Upon Innovation in Life Sciences? – London
Chaired by Sam Fazeli, Head of European Research and Pharmaceuticals Analyst at Bloomberg Intelligence, the panel who will consist of prominent speakers from the financial sector and biotech industry will consider the megafund concept:
- How it should be shaped
- What level of capital could be efficiently deployed
- Consider whether quantitative easing could be used to finance healthcare innovation and its adoption
See who else is on our panel and for more information, click read more below!